MYC and ovarian cancer: When we tested these agents in the MOSE-HRas-Myc mouse ovarian cancer cells, which have a highly aggressive proliferative behavior, only APCS-540 and APCS-643 (p = .03 at 2.4 μM vs. control, and p = .02 at 4.8 μM vs. control) demonstrated significant anti-tumor effects compared to Metavert, APCS-644, and SAHA (Fig. 2).